Top Private Equity News, Member Posts, Managed Futures Daily Indices and more!

3yrs ago Private Equity privateequitywire Views: 82

Kester completes hat-trick of refinancings

Submitted 26/02/2021 - 10:08am

Kester Capital, a primary buyout specialist, has successfully refinanced three of its portfolio companies following strong revenue and profit growth over the last 18 months.  

Kester’s sector focus and track record has resulted in strong lender appetite for three of its portfolio companies: Avania, YouGarden and Frontier Medical.
 
The deals come following a busy start to the year for Kester which recently announced its investment in drug discovery business, Optibrium, as well as the expansion of its investment team with a run of new hires.
 
Avania is a leading, global full-service contract research organisation focused on the management of clinical studies for medical devices, IVDs, biologics, and device-drug combination products internationally.  Headquartered in the Netherlands, Kester Capital acquired the business in 2016 and has driven an increasingly global presence through organic and acquisitive growth. Since Kester’s initial investment the business has more than quadrupled its revenue.  The deal sees Avania refinance its existing banking facilities with Crescent Capital which will enable Kester to position Avania well for its next phase oforganic and acquisitive growth.
 
Headquartered in Lincolnshire, YouGarden is the UK’s leadingspecialist e-commerce retailer of horticultural products. Over the last five years the business has delivered an organic compound annual growth rate of over 50 per cent. This impressive revenue growth has been accelerating due to the increasing trend of consumers to shop online. Coupled with a high level of profit conversion, the business was able to secure increased facilities from Santander and deliver a strong return to shareholders.
 
Frontier Medical, headquartered in Wales, is a specialist medical device business focused on the global pressure area care market. Since Kester Capital’s involvement, the business has seen significant international expansion and a broadening of the offering through new product development. These initiatives have seen export revenues grow by 160% and total revenues by over 60 per cent. Last summer, Frontier sold its non-core infection prevention division and following this has secured new loan facilities from Crescent Capital. As a result of the refinancing, Kester has now returned over 2x its original investment in Frontier. 
 
Cameron Crockett, Managing Partner of Kester Capital, says: “We are delighted to have secured refinancings for three of our portfolio companies, a real testament to the strength of the portfolio and the excellent performance of these businesses in challenging circumstance. We continue to be a supportive partner to Avania, YouGarden and Frontier and we are delighted that both Crescent Capital and Santander were able to deliver attractive debt packages to support continued development within these market leading businesses.”
 

Author Profile Tags Deals & Transactions

Today's Private Equity Headlines:

Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.